CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In detail, Danusertib exerts growth inhibition in immortalized BCR-ABL1-positive cells and in CML CD34-positive progenitors derived from patients sensitive or resistant to TKIs [111, 112].